Opposition in India to patent extension for Janssen's TB drug
Two tuberculosis survivors have opposed a patent application filed in India by Janssen Pharmaceutica, which they say could block generic versions of bedaquiline, a drug recommended for the treatment of multi drug resistant tuberculosis (MDR-TB), until 2027.
The drug has been caught in a patent battle and the opposition may boost chances of patients’ access to 'priority' anti-TB drug bedaquiline, reports The Pharma Letter’s India correspondent.
An estimated 2.79 million TB patients in India are added annually, according to the Ministry of Health and Family Welfare’s National Anti-Tuberculosis Drug Resistance Survey, 2016. India also has the highest share (24%) of drug resistant (DR-TB), and had around 135,000 DR-TB patients in 2017, of whom 124,200 (92%) had MDR-TB.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze